Intro text: 

46% of patients could be spared chemotherapy


The MINDACT trial sponsored and run by the European Organisation for Research and Treatment of Cancer  – involving 112 hospitals in 9 countries from 7 BIG collaborative groups – represents a large academic effort towards de-escalating therapies.

The study was designed to evaluate the utility of adding the 70-gene test (Mammaprint®) to the standard clinicopathological criteria used to identify those patients with early-stage breast cancer who could be safely spared adjuvant chemotherapy without this significantly affecting their risk of disease recurrence.


Between 2007 and 2011 the trial enrolled 6,693 women with node-negative or 1-to-3 node positive breast cancer.

46% of the patients identified as high-risk for cancer recurrence based on traditional factors were identified as lowrisk when adding the MammaPrint test. Based on good outcome results without chemotherapy, the data suggested that chemotherapy provided no clinically meaningful benefit for these patients and could be safely omitted.

MINDACT gives hope to many women with node-negative or 1-to-3 node positive early breast cancer. The study’s results provide the highest level of evidence showing that Mammaprint could significantly de-escalate the use of adjuvant chemotherapy in the future, thereby improving the quality of life of a great many women confronted with the disease.

The primary results of MINDACT were published in 2016 in the New England Journal of Medicine.

Main Publications

70-gene prognosis signature can help doctors decide which patients would benefit from chemotherapy or not